痛风患者使用非布司他或苯溴马隆的肝毒性风险:一项倾向评分匹配队列研究
本研究基于电子病历数据库,纳入痛风患者中使用非布司他或苯溴马隆且用药后一年内至少监测肝功能三次的新使用者,按年龄、性别及治疗前丙氨酸氨基转移酶(ALT)和天冬氨酸氨基转移酶(AST)进行1:1倾向评分匹配。匹配后非布司他组488例与苯溴马隆组488例,平均随访1.20年,非布司他组肝毒性发生率为39.6/1000人年,苯溴马隆组为16.8/1000人年,非布司他使用与显著更高的肝毒性风险相关(校正HR 2.75,95%CI 1.28-5.91)。
要点
- 匹配后非布司他组肝毒性发生率为39.6/1000人年,苯溴马隆组为16.8/1000人年。
- 非布司他使用与显著更高的肝毒性风险相关(校正HR 2.75,95%CI 1.28-5.91)。
- 基线转氨酶升高的患者中非布司他相关肝毒性风险尤为明显。
核心结论
- 在痛风患者中,非布司他使用与相比苯溴马隆显著更高的轻至中度肝功能异常风险相关。
研究设计与样本
- 基于电子病历数据库的倾向评分匹配队列研究,纳入使用非布司他或苯溴马隆且用药后一年内至少监测肝功能三次的痛风新使用者。
- 按年龄、性别及治疗前ALT和AST进行1:1倾向评分匹配,匹配后非布司他组488例、苯溴马隆组488例,平均随访1.20年。
- 采用Kaplan-Meier分析估计肝毒性概率(定义为ALT或AST>3倍正常上限),Cox回归计算风险比(HR)及95%置信区间(CI),并按年龄、体重指数及合并症进行亚组分析。
主要发现
- 共2338例痛风患者符合条件,37%的患者出现常见不良事件评价标准第5版1至3级AST或ALT异常。
- 匹配后非布司他组肝毒性发生率为39.6/1000人年,苯溴马隆组为16.8/1000人年。
- 非布司他使用与显著更高的肝毒性风险相关(校正HR 2.75,95%CI 1.28-5.91),尤其在基线转氨酶升高的患者中。
- 预设亚组分析结果未见差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to evaluate and compare the risk of hepatotoxicity associated with the use of febuxostat and benzbromarone in patients with gout. METHODS: New users of febuxostat or benzbromarone with monitoring of liver function at least three times in a year after initiation of the study drugs were identified from an electronic medical record database. Propensity score matching (PSM) was performed between the two groups 1:1 matched for age, sex, and pretreatment alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Kaplan-Meier analysis was used to estimate the probability of hepatotoxicity (defined as ALT or AST > 3× upper limit of normal). Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox regression. Subgroup analysis was performed based on age, body mass index, and comorbidities. RESULTS: A total of 2,338 patients with gout were eligible. A total of 37% of patients experienced Common Terminology Criteria for Adverse Events version 5 grades 1 to 3 for AST or ALT abnormality. After PSM, 488 febuxostat users were matched, with 488 participants receiving benzbromarone with a mean follow-up of 1.20 years. The incidence of hepatotoxicity was 39.6 and 16.8 per 1,000 person-years for febuxostat users and benzbromarone users, respectively. Febuxostat use was associated with a significantly greater risk of hepatotoxicity than benzbromarone (adjusted HR 2.75, 95% CI 1.28-5.91), especially in patients with elevated transaminases at baseline. Findings did not differ according to prespecified subgroups. CONCLUSION: Febuxostat use is associated with a significantly greater risk of mild-to-moderate perturbation of liver function compared to benzbromarone in patients with gout.
引用
- Sun W, Cui L, Terkeltaub R, et al. Risk of Hepatotoxicity in Patients With Gout Treated With Febuxostat or Benzbromarone: A Propensity Score-Matched Cohort Study. Arthritis Care Res (Hoboken). 2025. PMID: 40195679. doi:10.1002/acr.25547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。